← Back to Analyst Consensus 
ALLO Buy
Allogene Therapeutics, Inc.
Current Price —
Implied Upside —
Analysts 18
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Oct 29, 2026 (2 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Aug 17, 2026 | Citizens | reiterate | Market Outperform → Market Outperform | — | 47% |
| Apr 16, 2026 | JP Morgan | upgrade | Underweight → Neutral | — | 55% |
| Apr 16, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Apr 15, 2026 | Jefferies | maintain | Buy → Buy | — | 52% |
| Apr 14, 2026 | Bernstein | maintain | Market Perform → Market Perform | — | 52% |
| Apr 14, 2026 | Argus Research | maintain | Market Perform → Market Perform | — | 54% |
| Apr 14, 2026 | Citizens | maintain | Market Outperform → Market Outperform | — | 47% |
| Apr 14, 2026 | Baird | maintain | Outperform → Outperform | — | 55% |
| Apr 14, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Mar 13, 2026 | Canaccord Genuity | maintain | Buy → Buy | — | 48% |
| Mar 13, 2026 | Piper Sandler | maintain | Overweight → Overweight | — | 54% |
| Jan 9, 2026 | Citizens | upgrade | Market Perform → Market Outperform | $5 | 47% |
| Jan 7, 2026 | UBS | initiate | — → Buy | $8 | 54% |
| Oct 10, 2025 | JP Morgan | downgrade | Neutral → Underweight | $0 | 55% |
| Aug 4, 2025 | JMP Securities | reiterate | Market Perform → Market Perform | $0 | 53% |
| Aug 4, 2025 | JP Morgan | downgrade | Overweight → Neutral | $0 | 55% |
| Aug 1, 2025 | Oppenheimer | maintain | Outperform → Outperform | $7 | 52% |
| May 15, 2025 | Citigroup | maintain | Buy → Buy | $4 | 54% |
| May 14, 2025 | Truist Securities | maintain | Buy → Buy | $10 | 54% |
| May 14, 2025 | Piper Sandler | maintain | Overweight → Overweight | $7 | 54% |
| May 14, 2025 | RBC Capital | reiterate | Outperform → Outperform | $10 | 55% |
| May 14, 2025 | Oppenheimer | maintain | Outperform → Outperform | $9 | 52% |
| May 14, 2025 | Baird | maintain | Outperform → Outperform | $9 | 55% |
| Mar 19, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $8 | 44% |
| Mar 14, 2025 | Canaccord Genuity | maintain | Buy → Buy | $14 | 48% |
| Mar 14, 2025 | RBC Capital | reiterate | Outperform → Outperform | $10 | 55% |
| Mar 14, 2025 | Citizens Capital Markets | upgrade | Market Perform → Market Outperform | $5 | 49% |
| Nov 14, 2024 | Piper Sandler | maintain | Overweight → Overweight | $9 | 54% |
| Nov 8, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $9 | 44% |
| Oct 30, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $9 | 44% |
| Aug 15, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $9 | 44% |
| Aug 9, 2024 | Citigroup | maintain | Buy → Buy | $8 | 54% |
| Aug 9, 2024 | Truist Securities | reiterate | Buy → Buy | $14 | 54% |
| Aug 8, 2024 | Canaccord Genuity | maintain | Buy → Buy | $14 | 48% |
| May 31, 2024 | Piper Sandler | initiate | — → Overweight | $11 | 54% |
| May 21, 2024 | Oppenheimer | maintain | Outperform → Outperform | $13 | 52% |
| May 16, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $9 | 44% |
| May 15, 2024 | Truist Securities | maintain | Buy → Buy | $17 | 54% |
| May 14, 2024 | Stifel | maintain | Hold → Hold | $4.6 | 54% |
| Mar 19, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $10 | 44% |
| Mar 15, 2024 | RBC Capital | reiterate | Outperform → Outperform | $10 | 55% |
| Feb 27, 2024 | JP Morgan | maintain | Overweight → Overweight | $8 | 55% |
| Jan 19, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $10 | 44% |
| Jan 5, 2024 | Guggenheim | downgrade | Buy → Neutral | $0 | 52% |
| Jan 5, 2024 | JMP Securities | downgrade | Market Outperform → Market Perform | $0 | 53% |
| Dec 8, 2023 | Citigroup | initiate | — → Buy | $7 | 54% |
| Nov 15, 2023 | HC Wainwright & Co. | maintain | Buy → Buy | $12 | 44% |
| Sep 25, 2023 | JP Morgan | maintain | Overweight → Overweight | $9 | 55% |
| Aug 7, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $23 | 44% |
| Aug 3, 2023 | Oppenheimer | reiterate | Outperform → Outperform | $28 | 52% |
Price Target Trend
Jun 13, 2026 Oct 27, 2026
EPS Estimates
+1q —
0q —
+1y —
0y —
Cross-Platform Signals
No cross-platform signals in the last 90 days